Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication June 7, 2017
- Accepted for publication June 7, 2017
- Published online January 2, 2018.
Article Versions
- previous version (June 23, 2017 - 04:36).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2018 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Paul J. Roach1–3,
- Roslyn Francis2,4,5,
- Louise Emmett6,7,
- Edward Hsiao1,
- Andrew Kneebone1,3,
- George Hruby1,3,
- Thomas Eade1,3,
- Quoc A. Nguyen8,9,
- Benjamin D. Thompson8,9,
- Thomas Cusick8,9,
- Michael McCarthy10,
- Colin Tang4,5,
- Bao Ho11,
- Philip D. Stricker8,11 and
- Andrew M. Scott2,12–14
- 1Royal North Shore Hospital, Sydney, Australia
- 2Australasian Radiopharmaceutical Trials Network, Sydney, Australia
- 3University of Sydney, Sydney, Australia
- 4University of Western Australia, Perth, Australia
- 5Sir Charles Gairdner Hospital, Perth, Australia
- 6St Vincent's Hospital, Sydney, Australia
- 7University of New South Wales, Sydney, Australia
- 8The Garvan Institute of Medical Research, Sydney, Australia
- 9Australian Prostate Cancer Research Centre—New South Wales (APCRC-NSW), Sydney, Australia
- 10Fiona Stanley Hospital, Perth, Australia
- 11St Vincent's Prostate Cancer Centre, Sydney, Australia
- 12Austin Hospital, Melbourne, Australia
- 13Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia; and
- 14University of Melbourne, Melbourne, Australia
- For correspondence contact: Paul J. Roach, Department of Nuclear Medicine, Royal North Shore Hospital, St. Leonards, NSW, 2065, Sydney, Australia. E-mail: paul.roach{at}sydney.edu.au
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial)
- The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer
- Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes
- Detection Efficacy of 18F-rhPSMA-7.3 PET/CT and Impact on Management in Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy and Before Potential Salvage Treatment
- Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
- The Annual Journal Impact Factor Saga
- The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity
- Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial
- Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study
- Imaging the Distribution of Gastrin-Releasing Peptide Receptors in Cancer
- 3-Year Freedom from Progression After 68Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
- Radiation Dosimetry and Biodistribution of 18F-PSMA-11 for PET Imaging of Prostate Cancer
- Bridging the Imaging Gap: PSMA PET/CT Has a High Impact on Treatment Planning in Prostate Cancer Patients with Biochemical Recurrence--A Narrative Review of the Literature
- Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis
- Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade
- Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer
- 68Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients
- Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis
- Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer
- The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer